

wherein said drug is a biologically active therapeutic purine compound or a purine nucleoside or purine nucleotide compound and said azide group occurs on the 6-position of said purine compound or said purine nucleoside or nucleotide compound.

2-24. Cancelled.


25. (Previously presented) The composition according to claim 1 wherein said drug is a purine compound.

26. (Previously presented) The composition according to claim 1 wherein said drug is a purine nucleoside or purine nucleotide compound.

27. (Previously presented) The composition according to claim 26 wherein said drug is a purine nucleoside compound.

28. (Previously presented) The composition according to claim 26 wherein said drug is a purine nucleotide compound.

29. (Currently amended) The composition according to claim 1 wherein said azide derivative has the formula



wherein  $R_1$  is

(1) a substituted or unsubstituted furanose or dioxolane that is bound at the 1' position to the N 9 ring nitrogen of the purine of formula (I), or is  
(2) R<sub>3</sub>-OR<sub>4</sub>, where R<sub>3</sub> is a C<sub>2</sub>-C<sub>5</sub> alkyl, alkenyl, or alkynyl and -OR<sub>4</sub> is a C<sub>2</sub>-C<sub>5</sub> alkoxy carbonyl or alkoxy alcohol, and  
wherein R<sub>2</sub> is H, OH, NH<sub>2</sub>, or NHAc.

30. (Previously presented) The composition according to claim 29 wherein R<sub>1</sub> is furanose, R<sup>3</sup> is a C<sub>2</sub>-C<sub>5</sub> alkyl and -OR<sub>4</sub> is a C<sub>2</sub>-C<sub>5</sub> alkoxy alcohol.

31. (Previously presented) The composition according to claim 29 wherein R<sub>1</sub> is dioxolane.

REMARKS

This paper is a resubmission of an amendment filed July 28, 2004 with the patent office. The claims have been represented to conform more closely to the now pending rules of the Patent Office. No substantive change has been made from that previously submitted response. Claims 1 and 25-31 are pending in this application. Claims 2-6 and 7-23 have been cancelled or canceled/withdrawn from further consideration as being drawn to nonelected inventions or species. Applicants maintain that the instant amendments to claim 1 address all of the outstanding grounds for rejection imposed in the May 20, 2004 Office Action issued in the instant application and that each of pending claims 1 and 25-31 are in condition for allowance. Support for the amendment to the claims can be found throughout the original specification, examples and claims and in particular *inter alia*, at pages 9-10, page 11, scheme 1, page 12, scheme 2, page 13, scheme 3, page 14, lines 6-9 and 11-13, page 16, first full paragraph, page 17, third full paragraph, page 21, scheme 5, page 22, scheme 6, page 23, scheme 7, page 24, scheme 8, page 26, scheme 11 and page 27, scheme 12. No new matter has been added by way of the present invention.